Press Releases for October 23, 2019
advertisement
- Study on early detection of type 1 diabetes reaches milestone and continues
- Sernova Confirms Enduring Levels of Fasting C-Peptide in Bloodstream of First Patient in its Phase I/II Clinical Trial for Type-1 Diabetes
- FDA approves Fiasp® for use in insulin infusion pumps for adults with type 1 or type 2 diabetes (see also: FDA OKs Faster-Acting Insulin Aspart for Pump Use – free Medscape login required)